STANDARD BIOTOOLS INC.

B USINESS Overview At Standard BioTools, Inc. ("Standard BioTools" or the "Company"), we are committed to setting the new standard in the life science tools industry through strategic consolidation, best-in-class operations and a world class management team. Our established portfolio includes essential, standardized next-generation solutions designed to help biomedical researchers develop better therapeutics faster. We offer a diverse range of instrumentation, consumables, and services that generate high-quality data across early discovery, translational and clinical research. With advanced technologies in proteomics and genomics, we empower scientists to gain deeper biological insights, accelerate discoveries, and drive improved health outcomes across diverse therapeutic areas including immunology, oncology, neuroscience, cardiometabolic diseases and more. On June 22, 2025, we entered into a Stock Purchase Agreement (the Purchase Agreement ) with Illumina. Pursuant to the terms of the Purchase Agreement, Illumina acquired all of the equity interests of SomaLogic, Inc. ( SomaLogic ), Sengenics Corporation LLC ( Sengenics LLC ) and Sengenics Corporation Pte Ltd ( Sengenics Pte and together with Sengenics LLC, Sengenics ) (collectively, the Disposed Entities ), each a wholly owned subsidiary of the Company that operated the Company's aptamer-based and functional proteomics business, including KREX, Single SOMAmer, translational and diagnostic assays (collectively, the SomaScan Business ) (such transaction, the Transaction ).